Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13
Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $12 to $13.
Stocks · News reference
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $25 price target.
8-K filing — Intellia Therapeutics, Inc. (NTLA)
Filed: 2026-09-08 AccNo: 0001193125-26-385194 Size: 257 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits